Relay is a precision medicine company with a focus on understanding protein dynamics. The company is developing small molecule drugs for oncology, but its platform has broader applicability. Relay's ...
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results